Evidence map›Paper›PMID 40736936›Full record

ArticleBreast cancer (Tokyo, Japan)2025

Internal mammary node failure in invasive breast cancer patients who received post-operative radiotherapy without prophylactic internal mammary node irradiation.

Yasushi Hamamoto, Kenji Makita, Kei Nagasaki, Hiromitsu Kanzaki, Mariko Kochi, Michiko Yamashita, Mina Takahashi, Daisuke Takabatake, Kenjiro Aogi

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yasushi HamamotoDepartment of Radiation Therapy, NHO Shikoku Cancer Center, Matsuyama City, Japan. hamamoto.yasushi.gj@mail.hosp.go.jp.ORCID http://orcid.org/0000-0001-5324-7961
Kenji MakitaDepartment of Radiation Therapy, NHO Shikoku Cancer Center, Matsuyama City, Japan.
Kei NagasakiDepartment of Radiation Therapy, NHO Shikoku Cancer Center, Matsuyama City, Japan.
Hiromitsu KanzakiDepartment of Radiation Therapy, NHO Shikoku Cancer Center, Matsuyama City, Japan.
Mariko KochiDepartment of Breast Surgery, NHO Shikoku Cancer Center, Matsuyama City, Japan.
Michiko YamashitaDepartment of Breast Surgery, NHO Shikoku Cancer Center, Matsuyama City, Japan.
Mina TakahashiDepartment of Breast Surgery, NHO Shikoku Cancer Center, Matsuyama City, Japan.
Daisuke TakabatakeDepartment of Breast Surgery, NHO Shikoku Cancer Center, Matsuyama City, Japan.
Kenjiro AogiDepartment of Breast Surgery, NHO Shikoku Cancer Center, Matsuyama City, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer (BC) patients who would benefit the most from prophylactic internal mammary node (IMN) irradiation have not been clearly identified. Risk factors for ipsilateral IMN failure in BC patients who received post-operative radiotherapy (PORT) without prophylactic IMN irradiation were investigated.

methodsBetween January 2012 and March 2013, unilateral invasive BC patients who had no clinically positive IMN and received PORT without prophylactic IMN irradiation after breast-conserving surgery or mastectomy were retrospectively reviewed. At that time, prophylactic IMN irradiation was not recommended for clinically negative IMN by Japanese BC guidelines. To identify risk factors of IMN failure, the following factors were assessed using univariate and multivariate analyses: primary tumor location, hormone receptor status, human epidermal growth factor receptor 2 (HER2), axillary node status, and administration of neoadjuvant chemotherapy (NAC).

resultsA total of 194 BC patients (median age, 53 years; pStage I, 92; pStage II, 57; pStage III, 17; received NAC, 28) were analyzed. Median follow-up time with CT and/or FDG-PET/CT was 110 months (range, 4-132 months). IMN failure-free rates were 99% at 5 year and 98% at 10 year. The 10-year overall survival rate was 93%. In multivariate analysis, hormone receptor negativity was the only significant unfavorable factor for IMN failure (Hazard ratio 20.389, [95% CI 1.601-259.610], p = 0.02).

conclusionsHormone receptor status may have a greater impact on IMN failure compared to the primary tumor location and axillary lymph node status in the modern systemic therapy era. Because our study was a small retrospective study, further large-scale studies are needed.

Indexed as

Breast NeoplasmsLymph NodesAdultAgedAged, 80 and overAxillaErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansLymphatic MetastasisMastectomyMastectomy, SegmentalMiddle AgedNeoadjuvant TherapyRadiotherapy, AdjuvantERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesInternal mammary nodePost-operative radiotherapyProphylactic radiotherapy

Identifiers

PMID40736936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.